NO20073791L - Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer - Google Patents

Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer

Info

Publication number
NO20073791L
NO20073791L NO20073791A NO20073791A NO20073791L NO 20073791 L NO20073791 L NO 20073791L NO 20073791 A NO20073791 A NO 20073791A NO 20073791 A NO20073791 A NO 20073791A NO 20073791 L NO20073791 L NO 20073791L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
derivatives useful
pyrazolylaminopyridine
pyrazolylaminopyridine derivatives
useful
Prior art date
Application number
NO20073791A
Other languages
English (en)
Other versions
NO341112B1 (no
Inventor
Paul Dermot Lyne
Dingwei Yu
Audrey Davies
Bin Wang
Tao Wang
Michelle Lamb
Peter Mohr
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20073791L publication Critical patent/NO20073791L/no
Publication of NO341112B1 publication Critical patent/NO341112B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår nye forbindelser med formel (I) og deres farmasøytiske preparater og metoder for deres anvendelse. Disse nye forbindelser tilveiebringer en behandling for kreft.
NO20073791A 2005-02-04 2007-07-20 (S)-5-fluor-2-(1-(5-fluorpyridin-2-yl)etylamino)-6-(5-isopropoksy-1H-pyrazol-3-ylamino)nikotinonitril eller et farmasøytisk akseptabelt salt derav NO341112B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65005305P 2005-02-04 2005-02-04
US65332905P 2005-02-16 2005-02-16
US72163305P 2005-09-29 2005-09-29
PCT/GB2006/000334 WO2006082392A1 (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20073791L true NO20073791L (no) 2007-08-30
NO341112B1 NO341112B1 (no) 2017-08-28

Family

ID=36177856

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073791A NO341112B1 (no) 2005-02-04 2007-07-20 (S)-5-fluor-2-(1-(5-fluorpyridin-2-yl)etylamino)-6-(5-isopropoksy-1H-pyrazol-3-ylamino)nikotinonitril eller et farmasøytisk akseptabelt salt derav

Country Status (29)

Country Link
US (2) US8324252B2 (no)
EP (2) EP2383268B1 (no)
JP (1) JP5139084B2 (no)
KR (1) KR101302945B1 (no)
CN (1) CN101155800B (no)
AR (1) AR056184A1 (no)
AT (1) ATE530545T1 (no)
AU (1) AU2006210710B2 (no)
BR (1) BRPI0606793A8 (no)
CA (1) CA2595834C (no)
CY (2) CY1115078T1 (no)
DK (2) DK1846394T3 (no)
ES (2) ES2375735T3 (no)
HR (1) HRP20110962T1 (no)
HU (1) HUE025671T2 (no)
IL (1) IL184674A (no)
ME (1) ME02645B (no)
MX (1) MX2007009437A (no)
MY (1) MY149512A (no)
NO (1) NO341112B1 (no)
NZ (1) NZ561145A (no)
PL (2) PL1846394T3 (no)
PT (2) PT2383268E (no)
RS (1) RS52061B (no)
SA (1) SA06270007B1 (no)
SI (2) SI2383268T1 (no)
TW (1) TWI370127B (no)
UY (1) UY29360A1 (no)
WO (1) WO2006082392A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
BRPI0610184A2 (pt) * 2005-05-16 2012-09-25 Astrazeneca Ab composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica
DK1945631T3 (da) 2005-10-28 2012-10-22 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
JP2010506914A (ja) * 2006-10-18 2010-03-04 メルク エンド カムパニー インコーポレーテッド アンドロゲン受容体モジュレーターとしての２−ヒドロキシ−２−フェニル／チオフェニルプロピオンアミド
WO2008053812A1 (en) * 2006-10-27 2008-05-08 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and medicinal use thereof
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP5524491B2 (ja) * 2008-03-04 2014-06-18 石原産業株式会社 ３−アミノ−２−クロロ−６−トリフルオロメチルピリジンの製造方法
TW201011017A (en) * 2008-08-19 2010-03-16 Astrazeneca Ab Chemical compounds 495-1
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
PL2589592T3 (pl) * 2010-06-30 2019-03-29 Fujifilm Corporation Nowe pochodne nikotynamidu lub ich sole
UY33517A (es) 2010-07-19 2012-02-29 Astrazeneca Ab Depósito farmacéutico para 5-fluoro-2-[[(1S)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1H-pirazol-3-il)amino]piridin-3-carbonitrilo?.
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
RU2576623C2 (ru) * 2011-12-28 2016-03-10 Фуджифилм Корпорэйшн Новое производное никотинамида или его соль
AU2013205306B2 (en) 2012-03-16 2015-09-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
EP2914585B1 (en) * 2012-11-05 2018-03-07 Emory University 7,8-dihydroxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
SI3179992T1 (sl) 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
EP3179991B1 (en) 2014-08-11 2021-10-06 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
CN107250116B (zh) 2014-12-23 2020-10-27 艾士盟医疗公司 3,5-二氨基吡唑激酶抑制剂
BR112018068681A2 (pt) 2016-03-16 2019-01-15 Bayer Cropscience Ag derivados de n-(cianobenzil)-6-(ciclopropil-carbonilamino)-4-(fenil)-piridina-2-carboxamida e compostos relacionados como pesticidas e agentes de proteção de plantas
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
WO2019201848A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
WO2020233645A1 (zh) 2019-05-21 2020-11-26 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
BR9908004A (pt) 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
IL148385A0 (en) 1999-09-10 2002-09-12 Merck & Co Inc Tyrosine kinase inhibitors
EP1246823A1 (en) 1999-12-28 2002-10-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
MXPA02007957A (es) 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
DK1282607T3 (en) 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
SK2002003A3 (en) 2000-08-31 2004-04-06 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
AU8664701A (en) 2000-09-01 2002-03-22 Glaxo Group Ltd Oxindole derivatives
US7071217B2 (en) 2000-09-01 2006-07-04 Smithkline Beecham Corporation Substituted oxindole derivatives as tyrosine kinase inhibitors
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
HUP0400639A3 (en) * 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
ES2275021T3 (es) 2001-09-27 2007-06-01 Smithkline Beecham Corporation Derivados de azoxoindol como inhibidores de trk proteina quinasa para el tratamiento de cancer y dolor cronico.
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005103010A2 (en) 2004-04-21 2005-11-03 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
AU2005289426A1 (en) 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
CA2588220A1 (en) 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
AU2005322855B2 (en) 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
EP1853602B1 (en) 2005-02-16 2010-07-14 AstraZeneca AB Chemical compounds
SI1853588T1 (sl) * 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
CN101208093A (zh) * 2005-04-27 2008-06-25 阿斯利康(瑞典)有限公司 吡唑-嘧啶衍生物在治疗疼痛中的用途
WO2006118231A1 (ja) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation シアノピリジン誘導体及びその医薬としての用途
CN101218229A (zh) * 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
BRPI0610184A2 (pt) * 2005-05-16 2012-09-25 Astrazeneca Ab composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica
DK1945631T3 (da) * 2005-10-28 2012-10-22 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
KR20090024270A (ko) * 2006-06-30 2009-03-06 아스트라제네카 아베 암 치료에 유용한 피리미딘 유도체
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use

Also Published As

Publication number Publication date
EP2383268B1 (en) 2015-09-02
PL2383268T3 (pl) 2016-02-29
IL184674A0 (en) 2007-12-03
HRP20110962T1 (hr) 2012-01-31
HK1163677A1 (en) 2012-09-14
RS52061B (sr) 2012-04-30
CA2595834C (en) 2013-04-30
KR20070107107A (ko) 2007-11-06
SA06270007B1 (ar) 2010-11-22
PT2383268E (pt) 2015-12-21
US8324252B2 (en) 2012-12-04
EP1846394A1 (en) 2007-10-24
US20080139561A1 (en) 2008-06-12
MY149512A (en) 2013-09-13
TWI370127B (en) 2012-08-11
KR101302945B1 (ko) 2013-09-06
JP5139084B2 (ja) 2013-02-06
EP1846394B1 (en) 2011-10-26
SI1846394T1 (sl) 2012-06-29
CN101155800A (zh) 2008-04-02
NZ561145A (en) 2011-02-25
US8835465B2 (en) 2014-09-16
AU2006210710A1 (en) 2006-08-10
HUE025671T2 (en) 2016-04-28
CA2595834A1 (en) 2006-08-10
DK2383268T3 (en) 2015-09-14
CY1115078T1 (el) 2016-12-14
IL184674A (en) 2012-07-31
DK1846394T3 (da) 2012-01-16
WO2006082392A1 (en) 2006-08-10
PT1846394E (pt) 2012-01-05
US20130090358A1 (en) 2013-04-11
ATE530545T1 (de) 2011-11-15
BRPI0606793A2 (pt) 2009-12-01
NO341112B1 (no) 2017-08-28
ES2375735T3 (es) 2012-03-05
AR056184A1 (es) 2007-09-26
EP2383268A1 (en) 2011-11-02
MX2007009437A (es) 2007-08-16
CN101155800B (zh) 2012-05-23
ME02645B (me) 2012-04-30
AU2006210710B2 (en) 2009-12-10
ES2555063T3 (es) 2015-12-28
CY1119077T1 (el) 2018-01-10
SI2383268T1 (sl) 2016-02-29
BRPI0606793A8 (pt) 2018-03-13
UY29360A1 (es) 2006-10-02
HK1114374A1 (en) 2008-10-31
PL1846394T3 (pl) 2012-04-30
JP2008528664A (ja) 2008-07-31

Similar Documents

Publication Publication Date Title
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20090628L (no) Pyridizinon derivativater
NO20071593L (no) Pyrimidinderivater
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
UA94129C2 (ru) Соединения для ингибирования митоза
NO20063449L (no) Substituerte heterocykler og deres anvendelse
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
DK1853602T3 (da) Kemiske forbindelser
CY1108275T1 (el) Χημικες ενωσεις
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
NO20085212L (no) Nye pyridinanaloger
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20081217L (no) Nye benzotiazolonderivater
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
ATE527253T1 (de) Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer
SE0400284D0 (sv) Novel compounds

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees